普罗布考联合瑞舒伐他汀对短暂性脑缺血发作患者血液流变学及血清相关细胞因子水平的影响  

The Effect of Probucol Combined with Rosuvastatin on Hemorheology and Serum Levels of Related Cytokines in Patients with Transient Ischemic Attack

作　　者：鹿滨麒 陶录岭 LU Binqi;TAO Luling(Nanyang Second People's Hospital,Nanyang Henan 473000,China)

机构地区：[1]南阳市第二人民医院,河南南阳473000

出　　处：《药品评价》2024年第12期1503-1507,共5页Drug Evaluation

摘　　要：目的探究普罗布考与瑞舒伐他汀联合治疗短暂性脑缺血发作(TIA)患者的临床效果。方法选取2020年7月至2023年8月南阳市第二人民医院的95例TIA患者为研究对象,依据随机数字表法分为两组,在常规治疗基础上,对照组(n=47)予以瑞舒伐他汀治疗,观察组(n=48)予以瑞舒伐他汀联合普罗布考治疗。对比两组疗效,不良反应及治疗前后血液流变学[血浆黏度、纤维蛋白质、全血黏度(低切、高切)],氧化应激因子[丙二醛(MDA)、超氧化物歧化酶(SOD)],血脂[甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)],炎症因子[基质金属蛋白-9(MMP-9)、白细胞介素-6(IL-6)];并随访1年,统计两组不良事件发生率。结果观察组总有效率(91.67%)高于对照组76.60%(P<0.05)。治疗后观察组SOD、HDL-C较对照组高,纤维蛋白质、IL-6、LDL-C、MMP-9、血浆黏度、TG、MDA、TC、全血黏度(低切、高切)较对照组低(P<0.05)。两组不良反应对比,差异无统计学意义(P>0.05);随访1年两组不良事件发生率对比,差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合普罗布考治疗TIA患者效果可靠,可有效地改善患者血液流变情况,调节血脂,降低炎症及氧化应激反应,有助于患者预后恢复。Objective To explore the clinical effect of combination therapy of probucol and rosuvastatin in patients with transient ischemic attack(TIA).Methods A total of 95 patients with TIA in Nanyang Second People's Hospital from July 2020 to August 2023 were selected as the research subjects and divided into two groups according to the random number table method.On the basis of conventional treatment,the control group(n=47)was treated with rosuvastatin,while the observation group(n=48)was treated with rosuvastatin combined with probucol.The efficacy and the adverse effect of the two groups was compared,as well as hemorheology[plasma viscosity,fibrous protein,whole blood viscosity(low shear,high shear)],oxidative stress factor[malondialdehyde(MDA),superoxide dismutase(SOD)],blood lipid[triglyceride(TG),low density lipoprotein cholesterol(LDL-C),total cholesterol(TC)and high density lipoprotein cholesterol(HDL-C)before and after treatment.The patients were followed up for 1 year,and the incidence of adverse events in the two groups was statistically analyzed.Results The total effective rate of the observation group was 91.67%,which was higher than that of the control group,which was 76.60%(P<0.05).After treatment,the observation group had higher levels of SOD and HDL-C than the control group,while fibrin,IL-6,LDL-C,MMP-9,plasma viscosity,TG,MDA,TC,and whole blood viscosity(low shear and high shear)were lower than the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).There was no significant difference in the incidence of adverse events between the two groups after one-year follow-up(P>0.05).Conclusion The combination of rosuvastatin and probucol is effective in treating TIA patients,effectively improving their hemorheology,regulating blood lipids,reducing inflammation and oxidative stress,and helping patients recover.

关 键 词：短暂性脑缺血发作 普罗布考 炎症 氧化应激 瑞舒伐他汀 

分 类 号：R743.3[医药卫生—神经病学与精神病学]